A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Sponsor: Eisai Inc.
This PHASE3 trial investigates Non-Small Cell Lung Cancer (NSCLC) and is currently completed. Eisai Inc. leads this study, which shows 12 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jan 2021 — Jul 2023 [monthly]
Completed PHASE3
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE3
-
May 2017 — Oct 2017 [monthly]
Completed PHASE3
-
Feb 2017 — May 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Dec 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eisai Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Akashi-shi, Japan , Aschaffenburg, Germany , Aurora, United States , Aviano, Italy , Barcelona, Spain , Barnaul, Russia , Bordeaux, France , Chūōku, Japan , Cologne, Germany , Cremona, Italy and 72 more locations